Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Pharmaceutical
UK-based specialty pharmaceutical company CNX Therapeutics today announced it has successfully completed the acquisition of four cancer support products from Clinigen, a global pharmaceutical services company. 11 August 2023
Biotechnology
The US Food and Drug Administration (FDA) has granted approval for Talvey (talquetamab-tgvs) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. 11 August 2023
Biotechnology
Following the approval of toripalimab, the drug is expected to get a first-mover advantage in the first-line treatment setting within the PD-1 market in RCC for China, says data and analytics company GlobalData. 11 August 2023
Pharmaceutical
San Diego, USAbased cancer specialist Mirati Therapeutics is to replace its chief executive, David Meek, with former CEO Charles Baum taking over on an interim basis. 10 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday issued a Complete Response Letter (CRL) regarding US drug developer Galera Therapeutics New Drug Application (NDA) for avasopasem manganese for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. 10 August 2023
Biotechnology
First granted US accelerated approval in 2020, the Food and Drug Administration on Wednesday converted this to regular approval of Gavreto (pralsetinib) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 10 August 2023
Pharmaceutical
The competition to address two areas of huge unmet medical need is heating up, and Eli Lilly has a chance of being the leader in both. 8 August 2023
Pharmaceutical
Germany’s Bayer might have a new chief executive in Bill Anderson, but many of the challenges faced by his predecessor Werner Baumann remain. 8 August 2023
Biotechnology
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
Pharmaceutical
UK-based Astex Pharmaceuticals, a pharma company focused on the discovery and development of small molecules for oncology and central nervous system disorders, has expanded its deal with Merck & Co. 8 August 2023
Biotechnology
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Biotechnology
US cancer drug developer Ikena Oncology today announced the closing of its acquisition of privately-held clinical-stage biotech Pionyr Immunotherapeutics in an all-stock transaction. 7 August 2023
Biotechnology
Increased activity and investment in the development of antibody-drug conjugates (ADCs) has been evident in the oncology market in the past two to three years. 7 August 2023
Biotechnology
Shares of UK-based biotech Roquefort Therapeutics were up 9.3% at 8.88 pence by early afternoon, as it announced the successful development of new siRNA sequences and new patent filing for its family of novel anti-cancer siRNA therapeutics. 7 August 2023
Biotechnology
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Biotechnology
US biotech major Amgen has announced financial results for the second quarter of 2023. 4 August 2023
Pharmaceutical
Life sciences company Merck KGaA revealed declining sales and profits in its latest quarterly sales figures, but the sums still exceeded the expectations of analysts. 3 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil), developed by Taiho Oncology Inc and Taiho Pharmaceutical, subsidiaries of Japanese drugmaker Otsuka Holdings, with the decision coming ahead of the August 13 expected date. 3 August 2023
Biotechnology
Privately-held USA-based CG Oncology, previously known as Cold Genesys, has announced the closing of an oversubscribed $105 million crossover financing round. 3 August 2023
Biotechnology
US biotech Seagen, the subject of a $43 billion takeover by US pharma giant Pfizer, today reported financial results for the second quarter ended June 30, 2023, highlighting record net product sales, with significant year-over-year growth of 26% to $544 million 2 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze